|
TearSolutions
|
|
TearSolutions, Inc is an American biopharmaceutical development company based in Virginia and incorporated in Delaware. History TearSolutions Inc., was cofounded by University of Virginia cell biologist Gordon W. Laurie, and ophthalmic executive Mark B. Logan. Gordon Laurie is a Professor of Cell Biology, Ophthalmology and Biomedical Engineering at the University of Virginia. Mark Logan was the Chairman, President and CEO of VISX, Inc. that developed and gained FDA approval for the vision correcting procedure known as LASIK. TearSolutions is one of 50 University of Virginia-spinoff companies. The company was formed to complete preclinical, formulation and human clinical trial studies of a synthetic peptide of the natural tear protein lacritin discovered by the National Eye Institute supported Laurie lab out of a screen for novel factors capable of regulating basal tearing, the kind of tearing deficient in dry eye. Funding TearSolutions closed its Series A fundraising round on November 5, 2015 at $3M with Launch Capital as the lead venture capital firm, and with significant investment from the Medarva Innovations, LLC and Santen Pharmaceutical company. Other investors include Virgina's Center for Innovative Technology, and officers and advisors of the company. Operations TearSolutions subcontracts all of its operations. Subcontractors include Covance Inc., and Dow Development Laboratories, LLC. investigational new drug (IND) enabling studies are underway. 
|
| < Prev | Next > |
|---|
Main Menu
| Home |
| Articles |
| Search |
| Submit Article |
| Contact Us |
| Donate to Wikibin |
